

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/565,068
Filing Date	July 13, 2006
First Named Inventor	Parry John Guilford
Art Unit	1643
Examiner Name	Alana Harris
Attorney Docket Number	PEBL-01006US1

Sheet 2 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	European Examination Report dated Oct. 6, 2010 in Application No. 04778461.6 - 1222 / 1649064	
	2	DEZWART, LOECKIE, L., Biomarkers of free radical damage applications in experimental animals and in humans, Free Radical Biology & Medicine, Vol. 26, Nos. 1/2, pp. 202-226, 1999	
	3	SALMELA, MT, Parallel expression of macrophage metalloelastase (MMP-12) in duodenal and skin lesions and patients with dermatitis herpetiformis, GUT online, Gut2001;48;496-502	
	3	13 April 2008	
	4	FINLAY, MARTIN BJ, Prostate Cancer Prostatic Dis. 2004 Mar 9, PubMed, Louisiana University Health Sciences Center, New Orleans, LA.	
	5	Japanese Office Action translation.	
	6	YOSHIKAWA, TAKAKI, Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer, Elsevier, Cancer Letters 151 (2000) 81-86	
	7	RUDLAND, PHILIP S., Prognostic Significance of the Metastasis-associated Protein Osteopontin in Human Breast Cancer, Cancer Research 62, 3417-3427, June 15, 2002	
	8	Taiwanese Office Action, translation	
	9	BUCKHAULTS, PHILLIP, Secreted and cell surface genes expressed in benign and malignant colorectal tumors, Cancer Research 61, 6996-7001, October 1, 2001	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/565,068
Filing Date	July 13, 2006
First Named Inventor	Parry John Guilford
Art Unit	1643
Examiner Name	Alana Harris
Attorney Docket Number	PEBL-01006US1

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	10	HOTTE, SEBASTIAN J., Plasma Osteopontin, 2002, American Cancer Society	
	11	KIM, JAE-HOON, Osteopontin as a potential diagnostic biomarker for ovarian cancer, JAMA, American Medical Association, April 3, 2002, Vol. 287, No. 13. 1671-1682.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.